NCT02142738 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 151
- group Id
- BG002
- value
- 305
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg, administered as IV infusion on Day 1 of each 21-day cycle for up to 35 cycles or until documented PD or participant discontinuation.
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received 1 of 5 possible standard chemotherapy regimens at the investigator's discretion by IV infusion: paclitaxel 200 mg/m\^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\^2 and carboplatin AUC 5 or 6, on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\^2 and cisplatin 75 mg/m\^2, on Day 1 of each 21-day cycle for 4-6 cycles; gemcitabine 1250 mg/m\^2, administered on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, on Day 1 of a 21-day cycle, for 4-6 cycles; gemcitabine 1250 mg/m\^2, on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m\^2, on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. Participants with documented disease progression following chemotherapy can switch to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible participants who switched to and then stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (approximately 1 additional year).
- id
- BG001
- title
- SOC Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.1
- value
- 63.9
- group Id
- BG001
- spread
- 9.5
- value
- 64.6
- group Id
- BG002
- spread
- 9.8
- value
- 64.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 118
- title
- Female
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 187
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 283
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 46
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 251
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 107
- title
- ECOG = 0
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 98
- group Id
- BG002
- value
- 197
- title
- ECOG = 1
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- ECOG = 2
- description
- Eastern Cooperative Oncology Group (ECOG) Performance. ECOG is presented where 0 = Fully active, no performance restrictions; 1 = Strenuous physical activity restricted, fully ambulatory \& able to carry out light work; and 2 = In bed \<50% of the time, ambulatory and capable of all self-care, but unable to carry out any work activities.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Status (0, 1 or 2)
- unit Of Measure
- Rating
- classes
- categories
- measurements
- group Id
- BG000
- value
- 104
- group Id
- BG001
- value
- 108
- group Id
- BG002
- value
- 212
- title
- ADENOCARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- ADENOSQUAMOUS
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- LARGE CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 12
- title
- NON-SQUAMOUS CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 12
- title
- POORLY DIFFERENTIATED
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- SARCOMATOID
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 55
- title
- SQUAMOUS CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA
- description
- Participants were categorized according to the histology of their carcinoma
- param Type
- NUMBER
- title
- Histology
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 133
- group Id
- BG001
- value
- 132
- group Id
- BG002
- value
- 265
- title
- Non-East Asia
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 40
- title
- East Asia
- description
- Count of Participants enrolled in sites in Non-East Asia and East Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region of Enrolling Site
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 151
- group Id
- BG002
- value
- 305
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg, administered as IV infusion on Day 1 of each 21-day cycle for up to 35 cycles or until documented PD or participant discontinuation.
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received 1 of 5 possible standard chemotherapy regimens at the investigator's discretion by IV infusion: paclitaxel 200 mg/m\^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\^2 and carboplatin AUC 5 or 6, on Day 1 of each 21-day cycle for 4-6 cycles; pemetrexed 500 mg/m\^2 and cisplatin 75 mg/m\^2, on Day 1 of each 21-day cycle for 4-6 cycles; gemcitabine 1250 mg/m\^2, administered on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, on Day 1 of a 21-day cycle, for 4-6 cycles; gemcitabine 1250 mg/m\^2, on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m\^2, on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. Participants with documented disease progression following chemotherapy can switch to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible participants who switched to and then stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (approximately 1 additional year).
- id
- BG001
- title
- SOC Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.1
- value
- 63.9
- group Id
- BG001
- spread
- 9.5
- value
- 64.6
- group Id
- BG002
- spread
- 9.8
- value
- 64.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 118
- title
- Female
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 187
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 135
- group Id
- BG002
- value
- 283
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 16
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 46
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 126
- group Id
- BG002
- value
- 251
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 107
- title
- ECOG = 0
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 98
- group Id
- BG002
- value
- 197
- title
- ECOG = 1
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- ECOG = 2
- description
- Eastern Cooperative Oncology Group (ECOG) Performance. ECOG is presented where 0 = Fully active, no performance restrictions; 1 = Strenuous physical activity restricted, fully ambulatory \& able to carry out light work; and 2 = In bed \<50% of the time, ambulatory and capable of all self-care, but unable to carry out any work activities.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Status (0, 1 or 2)
- unit Of Measure
- Rating
- classes
- categories
- measurements
- group Id
- BG000
- value
- 104
- group Id
- BG001
- value
- 108
- group Id
- BG002
- value
- 212
- title
- ADENOCARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- ADENOSQUAMOUS
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- LARGE CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 12
- title
- NON-SQUAMOUS CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 12
- title
- POORLY DIFFERENTIATED
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- SARCOMATOID
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 55
- title
- SQUAMOUS CELL CARCINOMA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA
- description
- Participants were categorized according to the histology of their carcinoma
- param Type
- NUMBER
- title
- Histology
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 133
- group Id
- BG001
- value
- 132
- group Id
- BG002
- value
- 265
- title
- Non-East Asia
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 40
- title
- East Asia
- description
- Count of Participants enrolled in sites in Non-East Asia and East Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region of Enrolling Site
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle